| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yves Dauvilliers, Juliane Winkelman. Restless legs syndrome: update on pathogenesis. Current opinion in pulmonary medicine. vol 19. issue 6. 2014-06-03. PMID:24048084. |
much recent progress has been made in understanding restless legs syndrome (rls), focusing mainly on genetic predisposition and dysregulation of iron metabolism and the dopaminergic system. |
2014-06-03 |
2023-08-12 |
Not clear |
| Maria A T Cippà, Christian R Baumann, Massimiliano M Siccoli, Claudio L Bassetti, Rositsa Poryazova, Esther Wert. Actigraphic assessment of periodic leg movements in patients with restless legs syndrome. Journal of sleep research. vol 22. issue 5. 2014-04-28. PMID:23530689. |
the diagnosis of restless legs syndrome (rls) relies upon diagnostic criteria which are based on history only, and dopaminergic treatment is not normally the first choice of treatment for all patients. |
2014-04-28 |
2023-08-12 |
Not clear |
| Richard P Allen, Crystal Chen, Diego Garcia-Borreguero, Olli Polo, Sarah DuBrava, Jeffrey Miceli, Lloyd Knapp, John W Winkelma. Comparison of pregabalin with pramipexole for restless legs syndrome. The New England journal of medicine. vol 370. issue 7. 2014-02-25. PMID:24521108. |
dopaminergic medications relieve symptoms of the restless legs syndrome (rls) but have the potential to cause iatrogenic worsening (augmentation) of rls with long-term treatment. |
2014-02-25 |
2023-08-12 |
Not clear |
| Eva C Schulte, Nadine Gross, Helen Slawik, Juliane Winkelman. When restless legs syndrome turns malignant. Sleep medicine. vol 14. issue 6. 2014-02-04. PMID:23643657. |
usually symptoms of restless legs syndrome (rls) respond well to treatment with dopaminergic drugs, opiates, or anticonvulsant medications. |
2014-02-04 |
2023-08-12 |
Not clear |
| Claudia Trenkwalder, Heike Beneš, Ludger Grote, Diego García-Borreguero, Birgit Högl, Michael Hopp, Björn Bosse, Alexander Oksche, Karen Reimer, Juliane Winkelmann, Richard P Allen, Ralf Kohne. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. The Lancet. Neurology. vol 12. issue 12. 2014-01-14. PMID:24140442. |
we investigated the efficacy and safety of a fixed-dose combination of prolonged release oxycodone-naloxone for patients with severe restless legs syndrome inadequately controlled by previous, mainly dopaminergic, treatment. |
2014-01-14 |
2023-08-12 |
Not clear |
| Karen S Ferreira, Alan Eckeli, Fabíola Dach, José G Special. Comorbidities, medications and depressive symptoms in patients with restless legs syndrome and migraine. Arquivos de neuro-psiquiatria. vol 71. issue 2. 2013-11-18. PMID:23306209. |
the pathophysiology of migraine and restless legs syndrome (rls) seems to involve inherited mechanism and dysfunction of the dopaminergic system. |
2013-11-18 |
2023-08-12 |
Not clear |
| Yasuyuki Sugi. Empirical Use of Dopaminergic Agents for Restless Legs Syndrome Could be Associated With a Risk of Iatrogenic Parkinson's Disease. Journal of clinical medicine research. vol 5. issue 6. 2013-10-30. PMID:24171062. |
empirical use of dopaminergic agents for restless legs syndrome could be associated with a risk of iatrogenic parkinson's disease. |
2013-10-30 |
2023-08-12 |
Not clear |
| Ketaki Bhalsing, K Suresh, Uday B Muthane, Pramod Kr Pa. Prevalence and profile of Restless Legs Syndrome in Parkinson's disease and other neurodegenerative disorders: a case-control study. Parkinsonism & related disorders. vol 19. issue 4. 2013-09-06. PMID:23333538. |
restless legs syndrome (rls) is associated with impaired central dopaminergic neurotransmission. |
2013-09-06 |
2023-08-12 |
Not clear |
| Hee-Young Shin, Jinyoung Youn, Won Tae Yoon, Ji Sun Kim, Jin Whan Ch. Restless legs syndrome in Korean patients with drug-naïve Parkinson's disease: a nation-wide study. Parkinsonism & related disorders. vol 19. issue 3. 2013-08-12. PMID:23047004. |
restless legs syndrome is a common neurologic disorder, and there is increasing evidence for a dopaminergic link between parkinson's disease and restless legs syndrome. |
2013-08-12 |
2023-08-12 |
Not clear |
| K W Kim, J H Jhoo, S B Lee, S D Lee, T H Kim, S E Kim, Y K Kim, I-Y Yoo. Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients. European journal of neurology. vol 19. issue 9. 2013-06-17. PMID:22435397. |
dopamine dysregulation in restless legs syndrome (rls) may be varied by the severity of rls, which could contribute to the conflicting results from previous functional neuroimaging studies on the central dopaminergic neurotransmission of rls. |
2013-06-17 |
2023-08-12 |
Not clear |
| Henrietta Bowden Jones, Sanju Georg. 'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome. BMJ case reports. vol 2011. 2013-05-24. PMID:22678941. |
dopaminergic agents are commonly used and effective treatments for restless legs syndrome (rls), a disabling sensorimotor disorder. |
2013-05-24 |
2023-08-12 |
Not clear |
| José Luiz Pedroso, Pedro Braga-Neto, André C Felício, Thais Minett, Elton Yamaguchi, Lucila Bizari Fernandes do Prado, Luciane Bizari C Carvalho, Lívia Almeida Dutra, Marcelo Queiroz Hoexter, Antônio José da Rocha, Rodrigo A Bressan, Gilmar Fernandes do Prado, Orlando Graziani Povoas Barsottin. Sleep disorders in Machado-Joseph disease: a dopamine transporter imaging study. Journal of the neurological sciences. vol 324. issue 1-2. 2013-05-21. PMID:23137414. |
sleep disorders, especially restless legs syndrome (rls) and rapid eye movement sleep behavior disorder (rbd), are common in spinocerebellar ataxia type 3 or machado-joseph disease (mjd), and a possible underlying dopaminergic dysfunction is implicated. |
2013-05-21 |
2023-08-12 |
Not clear |
| R de la Fuente-Fernánde. The powerful pre-treatment effect: placebo responses in restless legs syndrome trials. European journal of neurology. vol 19. issue 10. 2013-04-11. PMID:22537387. |
to investigate whether dopaminergic pre-treatment alters placebo and dopamine agonist responses in restless legs syndrome (rls). |
2013-04-11 |
2023-08-12 |
Not clear |
| Michael J Howell, Carlos H Schenc. Restless nocturnal eating: a common feature of Willis-Ekbom Syndrome (RLS). Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. vol 8. issue 4. 2013-01-07. PMID:22893772. |
to determine the frequency of nocturnal eating (ne) and sleep related eating disorder (sred) in restless legs syndrome (rls) versus psychophysiological insomnia (ins), and the relationship of these conditions with dopaminergic and sedative-hypnotic medications. |
2013-01-07 |
2023-08-12 |
Not clear |
| Cynthia L Comell. Sleep disorders in Parkinson's disease. Current treatment options in neurology. vol 10. issue 3. 2012-10-02. PMID:18579025. |
restless legs syndrome and periodic limb movements during sleep are treated with direct dopaminergic agonists at bedtime. |
2012-10-02 |
2023-08-12 |
Not clear |
| S R Schreglmann, A R Gantenbein, G Eisele, C R Bauman. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism & related disorders. vol 18. issue 2. 2012-09-17. PMID:22030321. |
dopaminergic drugs are the mainstay of treatment for restless legs syndrome (rls). |
2012-09-17 |
2023-08-12 |
Not clear |
| Sudhansu Chokrovert. Long-term management issues in restless legs syndrome. Movement disorders : official journal of the Movement Disorder Society. vol 26. issue 8. 2012-02-29. PMID:21538518. |
several short-term and some long-term open-label and double-blind clinical trials have demonstrated the efficacy and safety of dopaminergic treatment in restless legs syndrome. |
2012-02-29 |
2023-08-12 |
Not clear |
| Alex Iranzo de Riquer, Alberto Bergareche, Victor Campo. Sleep disorders in Parkinson disease. The neurologist. vol 17. issue 6 Suppl 1. 2012-02-21. PMID:22045324. |
the mechanisms by which this occurs and the different types of sleep disorders that a patient with parkinson disease may suffer (insufficient or fragmented sleep, persistent excessive daytime sleepiness, sudden onset of sleep episodes, obstructive sleep apnea (osa), rapid eye movement sleep behavior disorder, and restless legs syndrome) will be reviewed in this study, as well as their relationship with the dopaminergic system. |
2012-02-21 |
2023-08-12 |
Not clear |
| Valerie Voon, Andrea Schoerling, Sascha Wenzel, Vindhya Ekanayake, Julia Reiff, Claudia Trenkwalder, Friederike Sixel-Dörin. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC neurology. vol 11. 2012-01-23. PMID:21955669. |
frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. |
2012-01-23 |
2023-08-12 |
Not clear |
| Jana Martinkova, Ludmila Trejbalova, Michaela Sasikova, Jan Benetin, Peter Valkovi. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clinical neuropharmacology. vol 34. issue 5. 2012-01-12. PMID:21738024. |
it was recently reported that icds are associated with other disorders also treated with dopaminergic drugs (dopamine agonists) such as restless legs syndrome, multiple system atrophy, progressive supranuclear palsy, and fibromyalgia. |
2012-01-12 |
2023-08-12 |
Not clear |